Key result
Niacin/laropiprant fails to improve postprandial triglycerides and worsens insulin resistance in obese women with PCOS.
Why the study?
Does niacin/laropiprant improve cardiovascular risk markers and insulin resistance in obese women with PCOS?
RCT (n=25)
Double-blind
randomized
Does niacin/laropiprant improve cardiovascular risk markers and insulin resistance in obese women with PCOS?
In obese women with PCOS, niacin/laropiprant improves fasting lipids but worsens insulin resistance and postprandial glucose, potentially negating cardiovascular benefits.
Answers are grounded in this paper and cite their sources.
Clinicians should avoid niacin/laropiprant in obese PCOS; challenges its role in CV risk reduction by worsening insulin resistance.
AIM: This study investigated the effect of long-term niacin/laropiprant therapy on CV risk and IR in obese women with PCOS. METHODS: In this double-blind randomized placebo-controlled trial, 13 and 12 PCOS women completed a 12 week course of niacin/laropiprant or placebo, respectively. Fasted subjects had an endothelial function test (EndoPat2000) and then consumed a mixed meal with blood sampled postprandially for 6 h before and after intervention. RESULTS: By 12 weeks, niacin/laropiprant lowered low-density lipoprotein cholesterol (LDL-c) (13%) and increased HDL-c (17%). Despite a reduction in fasting triglycerides (21%), the drug had no effect on their postprandial rise (2.69 ± 1.44 vs. 2.49 ± 1.14 mmol/l, p = 0.72). However, following the mixed meal, plasma glucose area under the response curve increased from 13.1 ± 2.9 to 14.0 ± 2.8 mmol/l, p = 0.05, as a consequence of both increased insulin resistance [HOMA-IR: 2.2 (1.2, 4.2) vs. 3.8(1.3, 5.5), p = 0.02] and a reduced acute insulin response to glucose [424 (211, 975) vs. 257(122, 418) pmol/mmol, p = 0.04]. Niacin/laropiprant did not improve RHI (1.97 ± 0.40 vs. 2.05 ± 0.58, p = 0.33) or hsCRP. CONCLUSIONS: In PCOS, niacin/laropiprant had a significant negative impact on postprandial glucose and no improvement in postprandial hypertriglyceridaemia, with at least the former mediated through increased IR and reduced β-cell function. This data may help explain why the improvement in fasting lipids has not translated into improved CV risk markers in PCOS.
No takes yet. Share an insight, caveat, or question.
Aye et al. (2014) conducted an RCT in Polycystic ovary syndrome (PCOS) (n=25). Niacin/laropiprant vs. Placebo was evaluated on Postprandial rise in triglycerides (mmol/l) (p=0.72). In obese women with PCOS, 12 weeks of niacin/laropiprant therapy did not improve the postprandial rise in triglycerides and worsened insulin resistance.
Synapse has enriched 10 related papers. Consider them for comparative context: